Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey


BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T. , ARSLAN Ö., GÖKER A. H. , ...More

17th International Myeloma Workshop, 12 - 15 September 2019

  • Publication Type: Conference Paper / Summary Text